Pyogenic Granuloma
Conditions
Interventions
Group A (Intratumoral Injection Group):Needle Entry Point: The needle was inserted vertically at the skin surface projection, either directly above or lateral to the tumor.
Puncture and Injection Pat
Group B (Compound Basal Injection Group) :Needle Entry Point: The needle was inserted through normal tissue approximately 2 mm from the margin of the lesion.
Puncture and Injection Path: The needle
Sponsors
Jinan Children's Hospital
Eligibility
Sex/Gender
All
Age
0.3 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age > 3 months, regardless of gender; 2.Met the typical clinical diagnostic criteria for PG, confirmed by color Doppler ultrasound; 3.Maximum lesion diameter ranging from 5 mm to 15 mm; 4.No prior treatment (such as surgical excision, laser therapy, cryotherapy, or sclerotherapy) for the target lesion; 5.No significant abnormalities in hepatic, renal, or coagulation functions; 6.Guardians fully understood the study protocols and signed the written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Known hypersensitivity or allergy to any component of the study drugs (polidocanol or lidocaine); 2.Concurrent severe cardiac, pulmonary, hepatic, renal, or hematological diseases; 3.Immunodeficiency or current use of immunosuppressive therapy; 4.Active infection at the lesion site; 5.Poor compliance of guardians, with an anticipated inability to complete the scheduled follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate at 4 weeks after the initial treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of treatment sessions required for cure;Degree of scarring;Satisfaction score; | — |
Countries
China
Contacts
Public ContactGuo Lei
Jinan Children's Hospital
Outcome results
None listed